Cochlear Ltd. (ASX:COH) announced today that it received FDA approval for three new products in its suite of implantable hearing technology.
Lone Tree, Colo.-based Cochlear won approval for its Nucleus Kanso 2 sound processor, Nucleus 7 sound processor for Nucleus 22 implant recipients and Custom Sound Pro fitting software, according to a news release.
Cochlear touts the Kanso 2 sound processor as the world’s smallest off-the-ear cochlear implant sound processor and the only implant of its kind to offer direct streaming from compatible Apple for Android devices. It features new charging options and high water resistance in a durable, all-in-one design with button-free control and automatic on/off function.
The Nucleus 7 sound processor is now compatible with the Nucleus 22 implant — Cochlear’s first commercial implant — meaning recipients can upgrade to Cochlear’s latest behind-the-ear sound processor with direct smartphone connectivity and streaming.
Cochlear’s Custom Sound Pro software supports clinicians programming the Nucleus sound processors with a new patient dashboard and goal-setting feature to promote engagement and effective progress tracking.
All three of the newly approved products will be commercially available in the U.S. and Canada later this year, according to the company.
“Cochlear continues to develop and introduce products to support the best lifelong hearing experience for our recipients and their care team,” Cochlear Americas president Tony Manna said in the news release. “Our new technology can better meet the individual needs and lifestyles of our recipients and is the result of persistent efforts to improve hearing outcomes.”